Subclinical hypothyroidism in addition to common risk scores for prediction of cardiovascular disease: a 10-year community-based cohort study

Tae Hyuk Kim, Hoon Sung Choi, Ji Cheol Bae1, Jae Hoon Moon2, Hyung-Kwan Kim, Sung Hee Choi2, Soo Lim2, Do Joon Park, Kyong Soo Park, Hak Chul Jang2, Moon-Kyu Lee1, Nam H Cho3 and Young Joo Park

Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, 3Department of Preventive Medicine, Ajou University School of Medicine, #5 Wonchon-Dong, Youngtong-Gu, Suwon 442-749, Korea

Abstract

Objective: This study was carried out to determine whether serum TSH levels improve the prediction of cardiovascular risk in addition to common clinical risk scores, given the association between subclinical hypothyroidism (SCH) and cardiovascular disease (CVD).

Design: We carried out an observational study in a prospective cohort.

Methods: The study included a total of 344 SCH and 2624 euthyroid participants aged over 40 years and who were without previously recorded CVDs were included in this study analysis. We measured thyroid function and traditional risk factors at baseline and estimated the 10-year cumulative incidence of CVD in a gender-stratified analysis.

Results: During 10 years of follow-up, 251 incident cardiovascular events were recorded. The elevation of serum TSH levels significantly increased the CV risk independent of conventional risk factors in men. In the atherosclerotic CVD (ASCVD) risk score or the Reynolds risk score (RRS) model, the addition of serum TSH levels had no effect on model discrimination as measured by the area under the curve in either women or men. Adding serum TSH did not improve the net reclassification improvement in either women (3.48% \( P = 0.29 \)) in the ASCVD, \(-0.89\% \( P = 0.75 \)) in the RRS, respectively) or men (\(-1.12\% \( P = 0.69 \), 3.45\% \( P = 0.20 \)), respectively) and only mildly affected the integrated discrimination Improvement in the ASCVD-adjusted model (0.30\% in women and 0.42\% in men, both \( P = 0.05 \)).

Conclusions: In the context of common risk scoring models, the additional assessment of serum TSH levels provided little incremental benefit for the prediction of CV risk.

Introduction

Cardiovascular disease (CVD), which is a major health problem worldwide, is the leading cause of death in the United States (1) and the second primary cause of death in Korea (2). In clinical practice, several clinical risk factors that can be easily measured are powerful predictors of CVD (3, 4). However, current prediction models cannot anticipate certain cases of incident CVD, thus motivating better prediction of the risk with alternative biomarkers.

Growing evidence indicates that higher serum thyroid-stimulating hormone (TSH) levels, even within
the reference range, are associated with worsening blood pressure (5) and lipid levels (6). Indeed, subclinical hypothyroidism (SCH), which is defined as an isolated elevation of TSH levels, is a quite common condition that occurs in 4–20% of the population (7); it is increasingly being recognised because thyroid function testing has been increased substantially in primary care (8). A recent large Taiwanese study has reported that SCH carried with it a 68% increased risk for CV mortality during a 10-year follow-up period (9). Despite the intuitive appeal of the relationship between TSH elevation or SCH and adverse CV outcomes, whether TSH testing would lead to an improvement in the prediction of CVD has not been established.

In this study, we sought to estimate the extent to which the inclusion of TSH can improve the risk stratification of clinical risk scores in a large, prospective, community-based cohort with different levels of overall CVD risk in a gender-stratified analysis.

Subjects and methods
Study population
The design of the Ansung cohort study and the demographics of participants have been described elsewhere (10). This ongoing, prospective cohort study is part of the Korean Health and Genome Study, which is a community-based epidemiological survey to investigate trends in chronic noncommunicable diseases and associated risk factors. The baseline examination was performed in 2001–2002, and the biennial follow-up examination is ongoing. The eligibility criteria included the following variables: age of 40–69 years, residence located within the border of the survey area for at least 6 months before testing, and sufficient mental and physical ability to participate in the study. A total of 5018 participants were recruited from the residents of Ansung, a representative rural farming community, using a two-stage cluster-sampling method stratified by age, sex, and residential district. Among the total participants, 3501 provided baseline blood samples that were stored in liquid nitrogen until the time of analysis to perform the thyroid function test (11). The excluded group was similar in gender ratio but slightly older than the study group (56.0 ± 8.7 vs 55.3 ± 8.9 years; P = 0.02).

We excluded 293 participants: subjects with a clinical history of CVD at baseline; those without follow-up data on CVD or mortality; those taking thyroxine, antithyroid agents, or medications that might interfere with thyroid function (i.e. amiodarone, antidepressants, and hormonal replacement); or those who had suffered from liver cirrhosis or cancer (12). Among the 3004 participants remaining, 344 (11.5%) participants with SCH and 2624 (87.4%) participants with euthyroidism at baseline were included in the final analysis. The proportion of participants lost to follow-up in the study population was similar to that in the total population (data not shown). Of the 36 excluded patients, six patients had overt thyroid dysfunction, and 30 (1.0%) patients had subclinical hyperthyroidism. Information about thyroid medication was extracted from the structured questionnaires at the follow-up visits.

As prior studies have shown the CV risks based on the degree of SCH, participants were categorised with regard to the degree of TSH elevation as exhibiting mild (4.1–6.9 mIU/l) and moderate/severe (≥ 7.0 mIU/l) degrees of elevation (13, 14). To assess the effect of TSH elevation on global CVD risk prediction over 10 years, we considered two widely cited and validated risk scores: the atherosclerotic CVD (ASCVD) risk score from the 2013 American College of Cardiology and the American Heart Association guidelines on the treatment of blood cholesterol (4) and the Reynolds risk score (RRS) (3), a model that includes additional information on biomarkers and data on family history. To mimic clinical practice, we used the published computational formulas for a 10-year cumulative risk rather than a refitted model using the ASCVD and the RRS covariates. Informed written consent was obtained from all of the participants. The study protocol was approved by the ethics committee of the Korean Center for Disease Control and the Ajou University School of Medicine Institutional Review Board.

Measurements of laboratory and anthropometric parameters
Each participant completed a structured questionnaire that included health-related questions concerning history of diabetes, hypertension, current smoking status and pharmaceutical information. Anthropometric parameters and blood pressure values were measured using standardised methods. The fasting plasma concentrations of glucose (reference range 74–106 mg/dl), total cholesterol (< 200 mg/dl), HDL cholesterol (40–60 mg/dl), highsensitivity C-reactive protein (< 1.0 mg/l) and standardised HbA1c (3.5–6.4%) were measured in a central laboratory. All of the participants underwent a 75 g oral glucose tolerance test (OGTT) at baseline. Diabetes was defined according to the American Diabetes Association criteria.
T H Kim and others

T SH and prediction of cardiovascular risk

Clinical Study

Evaluation of cardiovascular outcome

Study participants were monitored through December 2012 to determine the 10-year cumulative incidence of CVD events and all-cause mortality. A CVD event was defined as being diagnosed with myocardial infarction, angina, stroke, or CVD death by a physician at the participant’s clinical centre. Ascertainment of outcome was determined by direct interview and telephone contact during the prescheduled biennial visits and at the end of 10 years of follow-up. For deceased participants, additional information was gathered through visits with neighbours and visits to the district government mortality offices.

Statistical analysis

Continuous variables are expressed as the mean ± S.D. or as median (IQR) values, and categorical variables are presented as absolute counts and percentage. The hazard ratios (HRs) and 95% CIs of TSH levels (both in categorised and continuous variables) for the CVD events were calculated using gender-stratified Cox proportional hazard models, first unadjusted and subsequently adjusted for the two risk scores. We used unconditional logistic regression models to calculate the cumulative incidence function at the 10-year follow-up for each participant (16). We formally tested for interactions by including a product term between the risk scores and serum TSH level in the regression models and found that there was no evidence of any significant interaction. In addition, we performed lag time analysis to investigate the possible reverse causality (CVD leading to SCH) by relating baseline thyroid function testing with CVD incidence for a 2-year latency period between TSH measurement and the start of the at-risk period (17).

Using the area under the curve (AUC) of receiver-operating characteristic (ROC) curves, we evaluated the discriminatory capacity of the model that included TSH levels compared with the model without TSH levels. Model calibration across deciles of predicted risk was tested by a Hosmer–Lemeshow goodness-of-fit test. We assessed risk reclassification by sorting the predicted 10-year risk for each model into three categories (0 to <10%, 10 to <20%, and ≥20%). We evaluated risk reclassification using TSH levels according to the method developed by Pencina et al. (18) for determining the net reclassification improvement and the integrated discrimination improvement. Statistical analysis was performed using SPSS for Windows (version 19.0, IBM, Armonk, NY, USA). A P value <0.05 was considered to be statistically significant.

Results

The baseline clinical characteristics of 2624 euthyroid (1363 women and 1261 men) and 344 SCH (267 women and 77 men) participants stratified by gender are presented in Table 1. Significant differences in thyroid status were observed for smoking status in both women and men, and significant differences in free T4 levels, anti-TPO antibody positivity and BMI were observed in women only. Compared with the euthyroid men, men with SCH were significantly older and more likely to suffer hypertension and diabetes. Through the end of the 10-year follow-up, there were a total of 251 (8.5%) CV events: 31 myocardial infarction cases, 100 angina cases, 83 stroke cases and 37 CVD death cases. The number of patients who used thyroid medications during follow-up was not different between the event group and the non-event group (3 (1.2%) and 36 (1.3%) respectively). We included nine subjects (one in the SCH group and eight in the euthyroid group) who reported a medication history for dyslipidaemia at baseline because an analysis of the exclusion of the subjects did not reveal any differences (data not shown).

The cumulative incidence of CV events increased with increasing TSH levels in men (8.3%, 0.4–4.0 mIU/l; 16.1%, 4.1–6.9 mIU/l; and 26.7%, ≥10.00 mIU/l) but not in women (Table 2, and Supplementary Figure 1, see section...
Table 1 Baseline characteristics of the study population according to the thyroid status.

<table>
<thead>
<tr>
<th></th>
<th>Women (SCH n = 267)</th>
<th>Women (Euthyroid n = 1363)</th>
<th>P</th>
<th>Men (SCH n = 77)</th>
<th>Men (Euthyroid n = 1261)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (s.d.) (years)</td>
<td>56.0 (9.2)</td>
<td>55.1 (9.0)</td>
<td>0.13</td>
<td>58.9 (8.4)</td>
<td>54.9 (8.7)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>TSH, median (IQR) (mIU/l)</td>
<td>5.3 (4.6–6.8)</td>
<td>2.1 (1.4–2.9)</td>
<td></td>
<td>5.2 (4.5–6.5)</td>
<td>1.6 (1.1–2.2)</td>
<td></td>
</tr>
<tr>
<td>Free T4, mean (s.d.) (ng/dl)</td>
<td>0.9 (0.1)</td>
<td>1.0 (0.1)</td>
<td>&lt;0.01</td>
<td>1.0 (0.1)</td>
<td>1.0 (0.1)</td>
<td>0.33</td>
</tr>
<tr>
<td>Anti-TPO antibody-positivity, n (%)</td>
<td>68 (25.5)</td>
<td>132 (9.7)</td>
<td>&lt;0.01</td>
<td>8 (10.4)</td>
<td>65 (5.2)</td>
<td>0.06</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>64 (24.0)</td>
<td>329 (24.1)</td>
<td>0.95</td>
<td>21 (27.3)</td>
<td>225 (17.8)</td>
<td>0.04</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>39 (14.6)</td>
<td>183 (13.4)</td>
<td>0.61</td>
<td>17 (22.1)</td>
<td>172 (13.6)</td>
<td>0.04</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>1 (0.4)</td>
<td>63 (4.6)</td>
<td>&lt;0.01</td>
<td>31 (40.3)</td>
<td>693 (55.0)</td>
<td>0.01</td>
</tr>
<tr>
<td>Parental history of premature CAD, n (%)</td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>2 (0.2)</td>
<td>1.00</td>
</tr>
<tr>
<td>SBP, mean (s.d.) (mmHg)</td>
<td>123.4 (19.6)</td>
<td>122.5 (19.1)</td>
<td>0.47</td>
<td>125.3 (17.6)</td>
<td>121.5 (17.0)</td>
<td>0.06</td>
</tr>
<tr>
<td>DBP, mean (s.d.) (mmHg)</td>
<td>78.4 (11.2)</td>
<td>77.7 (10.5)</td>
<td>0.31</td>
<td>79.1 (9.4)</td>
<td>78.8 (10.1)</td>
<td>0.79</td>
</tr>
<tr>
<td>HDL, mean (s.d.) (mg/dl)</td>
<td>54.3 (10.0)</td>
<td>56.9 (11.3)</td>
<td>0.32</td>
<td>54.9 (10.2)</td>
<td>56.9 (11.3)</td>
<td>0.14</td>
</tr>
<tr>
<td>C-reactive protein, median (IQR) (mg/l)</td>
<td>1.6 (0.8–2.5)</td>
<td>1.5 (0.8–2.5)</td>
<td>0.51</td>
<td>1.8 (1.1–3.6)</td>
<td>1.6 (0.8–2.7)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

CAD, coronary artery disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; SCH, subclinical hypothyroid; TPO, thyroid peroxidase; TSH, thyroid-stimulating hormone.

on supplementary data). The cardiovascular hazards associated with increasing TSH categories were observed in both the ASCVD-adjusted and the RRS-adjusted models (both P<0.01 for trend) in men. When we analysed the TSH levels as continuous variables, the HR of CV events per 1-S.D. increase in TSH levels was 1.19 (P<0.01) in the ASCVD-adjusted model and 1.24 (P<0.01) in the RRS-adjusted model in men. As expected, the group of individuals older than 65 years suffered more CV events than the younger group (13.6 vs 7.1%, P<0.01). When we further stratified the subjects according to the age categories, this gender difference was decreased in older adult (Supplementary Table 1, see section on supplementary data). The presence of anti-TPO antibody did not affect the HR of CV events (Table 2). The association between TSH levels and CVD risk was unchanged when we performed stratified analyses for diabetes and BMI categories (classified as BMI <25, 25–30, >30 kg/m²) (P=0.19 for diabetes and 1.00 for BMI categories). When a 2-year lag period was imposed between TSH measurements and start of the at-risk period, the results were similar to the non-lagged analyses (data not shown).

Figure 1 displays ROC curves for prediction of a 10-year cumulative incidence of CV events. The addition of the TSH value to either the ASCVD or the RRS did not improve the discriminatory ability of the risk model applied in either women (ROC-AUC, 0.669–0.667 (P=0.95 for difference) and 0.672–0.672 (P=1.00 for difference), respectively) or men (0.669–0.681 (P=0.72 for difference) and 0.660–0.671 (P=0.75 for difference), respectively. Both the ASCVD and the RRS with TSH information remained calibrated.

The net reclassification and integrated discrimination improvement, as markers of improved risk reclassification obtained by means of TSH levels, are given in Table 3. Adding serum TSH did not improve the net reclassification improvement in either women (3.48% (P=0.29) in the ASCVD, −0.89% (P=0.75) in the RRS, respectively) or men (−1.12% (P=0.69), 3.45% (P=0.20), respectively) and only mildly affected the integrated discrimination improvement in the ASCVD-adjusted model (0.30% in women and 0.42% in men, both P=0.05).

Discussion

In this community-based prospective cohort followed for 10 years, we observed that an elevation of serum TSH levels significantly increased the CV risk by ~20% per 1-s.d. increase independent of conventional CV risk factors in men. However, when the information on TSH was included to predict the risk of CVD either with the ASCVD model or the RRS model, the predictability of each risk scoring model was not improved in either women or men. This finding suggests that there was no additional benefit afforded by screening for TSH when using the preexisting clinical scoring models to predict the CV risk, despite their association.
This study has clinical relevance because there is insufficient evidence to recommend for or against routine screening for subclinical thyroid dysfunction (19, 20), whereas measurement of serum TSH is one of the most frequently ordered tests in primary care (21). Based on the need for aggressive case finding, a previous consensus statement from three different academic committees favored routine screening for subclinical thyroid dysfunction in the general population until adequate data are accumulated (22). To the best of our knowledge, this report is the first prospective study that demonstrates that an isolated TSH elevation would not be an efficient discriminator of CV risk in asymptomatic individuals.

A possible explanation for this finding is that SCH increases the CV risk particularly in men; however, its impact is not as large compared with other metabolic derangements, such as dyslipidaemia, diabetes, and hypertension (23), for which management is already a part of standard care targeted at reducing CV risk. That is, those phenotypic risk factors are considerably stronger determinants of adverse CV events compared with SCH (24). Thus, the predictive power gained from the expanded TSH screening, if any, might not have an additional effect on the clinical risk factors commonly used in adults.

A previous meta-analysis of 55,287 individuals from 11 prospective cohorts reported an increased risk of coronary heart disease events and mortality in individuals with moderate/severe SCH (13). It is possible that as more independent CVD risk factors are included, the risk estimate improves; however, a significant statistical association does not necessarily lead to an improvement in the risk stratification for CV outcomes. By considering the TSH levels to be continuously distributed risk factors for a composite of adverse CV outcomes, our data extend these studies to demonstrate that the ability of serum TSH to differentiate subjects who do and do not develop CVD is minimal after consideration of other common risk factors. However, there is a likelihood that TSH levels might contribute more to the subsets of men with moderate/severe SCH or older adults, as can be inferred from the stratified analysis. In our previous reports, SCH subjects with intermediate to high risk (Adult Treatment Panel-III ≥ 10%) had higher coronary artery calcium scores than euthyroid subjects, especially in men (25). Marfella et al. (26) observed more inflammatory activity in the asymptomatic carotid plaques of SCH subjects than in euthyroid subjects. Of note, the negative effect of SCH on CV events may vanish in the oldest elderly individuals (> 80–85 years) with overwhelming comorbidities other than SCH (27, 28).
The difference in the impact of SCH between women and men with respect to CV outcomes has been reported in a few studies that presented gender-specific data (27). In a Danish cross-sectional study, SCH was a significant predictor of CV disease in young men aged less than 50 years (33). However, the gender differences were not observed in the study of 1101 older individuals aged more than 65 years (34). Consistent with previous studies, the risk of CV events was increased relative to increasing SCH categories in men, and it can be inferred from the baseline observation that men with SCH were more likely to have an adverse CV risk profile than women with SCH. This gender difference was evident in younger adult groups in our study, corresponding with the reduced SCH-associated CV risk in premenopausal women (35).

The current study has several strengths. The results came from a large, prospective, community-based cohort. There was a substantial number of CV events in the euthyroid and SCH groups during the 10 years of follow-up. We adapted new reclassification statistics, which are useful adjunct measures of discrimination in prospective data for quantifying the net increase vs the decrease in risk categories among case patients minus that among control participants (36). We also reported independence in multivariable regressions, discrimination in the AUC and calibration to describe the clinical contribution of TSH measurements in accordance with recent recommendations (37).

This study also has a number of weaknesses. First, the study was carried out in an area where there was sufficient iodine in a population of homogeneous Korean ethnic background; thus, these results might have limited applicability in areas where iodine is deficient, and caution is needed in extrapolating the study results to other ethnic groups. Second, we could not obtain results for subclinical hyperthyroidism because of its low prevalence in this iodine-sufficient population (38, 39). Because subclinical hyperthyroidism has been suggested to be associated with coronary artery disease (40) or stroke (41), we excluded this condition to avoid complexity in the analysis of two different conditions with limited statistical power. Third, among 26 patients with SCH and TSH higher than 10.0 mIU/l in our cohort, four patients developed CVD during follow-up, and only two patients who did not develop CVD used thyroid medications during follow-up. Generally, patients with severe SCH are recommended to be treated with thyroxine, as there is a consensus in its ability to reduce CV risk in younger patients aged less than 65–70 years (42). Using stored blood samples, we could not explain to

The reported benefits of SCH treatments were limited. Garber et al. (29) reported that the treatment benefit for those with screen-detected SCH is uncertain in the TSH range of 4.0–10.0 mIU/l outside of pregnancy. In 2007, a Cochrane review assessed 12 randomised controlled trials of thyroxine replacement in patients with SCH and concluded that treatment did not result in improved survival, reduced CV mortality, or improved health-related quality of life (30), whereas new data exist for improved outcomes of coronary heart disease in younger (<70 years), but not older, patients treated with thyroxine (31). Furthermore, SCH was associated with improved survival in a study of the elderly aged 85 years (28); any benefits may be offset by the potential adverse effects of replacement therapy, such as atrial fibrillation and osteoporosis, because the elderly are particularly susceptible to atrial fibrillation (32). In addition, postmenopausal women are prone to accelerated bone loss (29). Taken together with the present study, population screening for SCH should not be generalised but should be selectively applied only to the subjects who are expected to achieve an improved predictability of CV risk or benefit from thyroxine supplementation for SCH.

Figure 1
Receiver-operating characteristic curves for the atherosclerotic cardiovascular disease (ASCVD) risk score and Reynolds risk score (RRS) model with and without TSH levels. AUC, area under the curve; TSH, thyroid-stimulating hormone.
Table 3  Reclassification of 10-year cardiovascular risk according to the thyroid status for subjects in whom cardiovascular disease developed and for those in whom cardiovascular disease did not develop.

<table>
<thead>
<tr>
<th>Models without TSH</th>
<th>ASCVD model with TSH</th>
<th>RRS model with TSH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 to &lt;10% risk</td>
<td>10 to &lt;20% risk</td>
</tr>
<tr>
<td>Subjects in whom CVD developed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to &lt;10% risk</td>
<td>74</td>
<td>10</td>
</tr>
<tr>
<td>10 to &lt;20% risk</td>
<td>5</td>
<td>39</td>
</tr>
<tr>
<td>≥20% risk</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total no.</td>
<td>79</td>
<td>49</td>
</tr>
<tr>
<td>Subjects in whom CVD did not develop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to &lt;10% risk</td>
<td>1154</td>
<td>85</td>
</tr>
<tr>
<td>10 to &lt;20% risk</td>
<td>41</td>
<td>212</td>
</tr>
<tr>
<td>≥20% risk</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total no.</td>
<td>1195</td>
<td>297</td>
</tr>
<tr>
<td>Net reclassification improvement (%)</td>
<td>3.48</td>
<td>-0.89</td>
</tr>
<tr>
<td>P</td>
<td>0.29</td>
<td>0.75</td>
</tr>
<tr>
<td>Integrated discrimination improvement (%)</td>
<td>0.30</td>
<td>0.16</td>
</tr>
<tr>
<td>P</td>
<td>0.05</td>
<td>0.13</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects in whom CVD developed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to &lt;10% risk</td>
<td>24</td>
<td>1</td>
</tr>
<tr>
<td>10 to &lt;20% risk</td>
<td>8</td>
<td>81</td>
</tr>
<tr>
<td>≥20% risk</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total no.</td>
<td>32</td>
<td>83</td>
</tr>
<tr>
<td>Subjects in whom CVD did not develop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to &lt;10% risk</td>
<td>568</td>
<td>30</td>
</tr>
<tr>
<td>10 to &lt;20% risk</td>
<td>98</td>
<td>490</td>
</tr>
<tr>
<td>≥20% risk</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Total no.</td>
<td>666</td>
<td>525</td>
</tr>
<tr>
<td>Net reclassification improvement (%)</td>
<td>-1.12</td>
<td>3.45</td>
</tr>
<tr>
<td>P</td>
<td>0.69</td>
<td>0.20</td>
</tr>
<tr>
<td>Integrated discrimination improvement (%)</td>
<td>0.42</td>
<td>0.17</td>
</tr>
<tr>
<td>P</td>
<td>0.05</td>
<td>0.17</td>
</tr>
</tbody>
</table>

ASCVD, atherosclerotic cardiovascular disease risk score; CVD, cardiovascular disease; RRS, Reynolds risk score; TSH, thyroid-stimulating hormone.

the subjects the test results at the time of inclusion. Fourth, data on the use of aspirin, which could affect CV outcomes, was not available. However, the possibility of taking aspirin in the SCH group would be similar or greater than in the euthyroid group because of the worse metabolic profile in the former group. Therefore, the protective effect of aspirin would not jeopardise the study results demonstrating increasing CV risk in the SCH group. Fifth, we could not assess the changes in thyroid function because thyroid function testing was performed only at baseline. Although raised TSH is frequently transient, we recently reported that SCH individuals who converted to euthyroidism were still prone to develop SCH again (12). Moreover, a recent study using both multiple and first TSH data failed to show increased CV risk in older adults with SCH (43). Finally, even with adjustments for representative global CV risk scoring systems with TSH levels, the possibility of residual confounding variables remains, particularly for the intermediate-risk individuals, young women and in the assessment of short-term cardiovascular risk (9, 44).

In summary, an elevation of serum TSH levels significantly increased the CV risk in men; however, TSH levels did not improve the prediction of the CV risk when combined with the clinical risk factors commonly used in either women or men. Our data indicate that TSH screening might not be recommended for the prediction of CV risk for asymptomatic individuals.
Clinical Study
T H Kim and others
TSH and prediction of cardiovascular risk

171:5
656

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-14-0464.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported in part by Korea Centers for Disease Control and Prevention (contracts 2001347-6111-221, 2002-347-6111-221, 2003-347-6111-221, 2004-E71001-00, 2005-E71001-00, 2006-E71006-00, 2007-E71003-00, 2008-E71005-00, 2009-E71007-00, 2010-E71004-00, 2011-E71008-00, and 2012-E71008-00).

Author contribution statement
Dr Y J Park and N H Cho had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: T H Kim, K S Park, H C Jang, N H Cho, and Y J Park. Acquisition of data: J C Bae, S H Choi, S Lim, and M K Lee. Analysis and interpretation of data: T H Kim, H S Choi, J H Moon, H K Kim, and D J Park. Drafting of the manuscript: T H Kim, S Lim, H C Jang, N H Cho, and Y J Park. Critical revision of the manuscript for important intellectual content: H S Choi, J C Bae, J H Moon, H K Kim, S H Choi, D J Park, K S Park, and M K Lee. Statistical analysis: T H Kim, H S Choi, S Lim, N H Cho, and Y J Park. Obtaining funding: N H Cho. Administrative, technical, or material support: J C Bae, J H Moon, S H Choi, H C Jang, and Y J Park. Supervision: D J Park, K S Park, M K Lee, and N H Cho.

References
9 Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK & Huang KC. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. Journal of the American College of Cardiology 2012 60 730–737. (doi:10.1016/j.jacc.2012.03.047)


30 Razvi S, Weaver JU, Butler TJ & Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. *Archives of Internal Medicine* 2012 **172** 811–817.


33 Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN & Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. *Thyroid* 2003 **13** 595–600. (doi:10.1089/105072503322238863)


42 Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S & Wemeau JL. ETA guideline: management of subclinical hypothyroidism. *European Thyroid Journal* 2013 **2** 215–228. (doi:10.1159/000356507)


44 Cooney MT, Dudina AL & Graham IM. Value and limitations of thyroid hormone replacement for subclinical hypothyroidism. *Cochrane Database of Systematic Reviews* 2010 **9** CD003419.

Received 7 June 2014
Revised version received 11 August 2014
Accepted 1 September 2014

www.eje-online.org
Downloaded from Bioscientifica.com at 12/21/2018 09:07:48PM via free access